- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07703436
Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease
This study will include up to 40 participants with Grade 2 or Grade 3 IDH1-mutant glioma who have undergone surgery and received vorasidenib as their only treatment, experienced radiographic disease progression on vorasidenib (confirmed by Blinded Independent Central Review [BICR] per modified Response Assessment in Neuro-Oncology [RANO] 2.0), and are not in need of immediate chemotherapy or radiotherapy.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Clinical Trials at Nuvation Bio
- Telefonnummer: 332-208-6102
- E-post: ClinicalTrials@nuvationbio.com
Studiesteder
-
-
California
-
Los Angeles, California, Forente stater, 90095
- Har ikke rekruttert ennå
- University of California, Los Angeles
-
Hovedetterforsker:
- Robert Chong, MD
-
Ta kontakt med:
- Quan Li
- Telefonnummer: 310-825-1416
- E-post: quanli@mednet.ucla.edu
-
San Francisco, California, Forente stater, 94143
- Har ikke rekruttert ennå
- University of California, San Francisco
-
Hovedetterforsker:
- John De Groot, MD
-
Ta kontakt med:
- Neuro Onc New Patient Coordinator
- Telefonnummer: 415-353-2193
- E-post: neurooncnewpatientcoord@ucsf.edu
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06510
- Har ikke rekruttert ennå
- Yale University
-
Hovedetterforsker:
- Nicholas Blondin, MD
-
Ta kontakt med:
- Amy Rodrigues
- E-post: amy.rodrigues@yale.edu
-
Ta kontakt med:
- E-post: cto-neuro@yale.edu
-
-
Florida
-
Miami, Florida, Forente stater, 33136
- Har ikke rekruttert ennå
- University of Miami Health
-
Ta kontakt med:
- Leonela Wright
- Telefonnummer: 305-243-0864
- E-post: lxw612@med.miami.edu
-
Hovedetterforsker:
- Juan Blaquier, MD
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46202
- Rekruttering
- Indiana University
-
Hovedetterforsker:
- Kathryn Nevel, MD
-
Ta kontakt med:
- NeuroOncology Clinical Trials
- Telefonnummer: 3179634823
- E-post: neuroct@iu.edu
-
-
Louisiana
-
New Orleans, Louisiana, Forente stater, 70112
- Har ikke rekruttert ennå
- LSU LCMC Health Cancer Center
-
Hovedetterforsker:
- Yazmin Odia, MD
-
Ta kontakt med:
- Yazmin Odia
- Telefonnummer: (646) 634-9655
- E-post: yodia@lsuhsc.edu
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02214
- Har ikke rekruttert ennå
- Massachusetts General Hospital
-
Ta kontakt med:
- Vihang Nakhate
- Telefonnummer: 617-724-8770
- E-post: vnakhate@mgh.harvard.edu
-
Hovedetterforsker:
- Vihang Nakhate, MD
-
-
New Jersey
-
New Brunswick, New Jersey, Forente stater, 08901
- Har ikke rekruttert ennå
- Rutgers Cancer Institute
-
Hovedetterforsker:
- Morana Vojnic, MD
-
Ta kontakt med:
- Kasie Diorio
- Telefonnummer: 732-235-2465
- E-post: kassie.diorio@rutgers.edu
-
-
New York
-
New York, New York, Forente stater, 10016
- Rekruttering
- NYU Langone Health
-
Ta kontakt med:
- Jose McFaline-Figueroa, MD
- Telefonnummer: 212-731-6267
- E-post: Jose.McFalineFigueroa@nyulangone.org
-
New York, New York, Forente stater, 10032
- Har ikke rekruttert ennå
- Columbia University Medical Center
-
Hovedetterforsker:
- Andrew Lassman, MD
-
Ta kontakt med:
- Research Nurse Navigator
- Telefonnummer: 212-342-5162
- E-post: Cancerclinicaltrials@cumc.columbia.edu
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44106
- Har ikke rekruttert ennå
- Cleveland Clinic
-
Hovedetterforsker:
- Mina Lobbous, MD
-
Ta kontakt med:
- Marci Ciolfi
- Telefonnummer: 216-445-3307
- E-post: ciolfim@ccf.org
-
Columbus, Ohio, Forente stater, 43210
- Har ikke rekruttert ennå
- The Ohio State University Comprehensive Cancer Center
-
Ta kontakt med:
- Pierre Giglio
- Telefonnummer: 614-293-4448
- E-post: Pierre.Giglio@osumc.edu
-
Hovedetterforsker:
- Pierre Giglio, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Key Inclusion Criteria:
- Histologically confirmed Grade 2 or 3 IDH-mutant astrocytoma or IDH-mutant and 1p19q co-deleted oligodendroglioma, according to WHO CNS 2021 criteria
- IDH1 mutation (e.g., R132H/C/G/S/L) based on immunohistochemistry (IHC) (R132H only), PCR, or next generation sequencing (NGS).
- Have had at least 1 prior surgery for glioma (biopsy, sub-total resection, or gross total resection).
- Measurable disease per modified RANO 2.0 confirmed by BICR during Screening.
- Previously treated with vorasidenib and experienced radiographic disease progression during treatment and are not in need of immediate chemotherapy or radiotherapy in the opinion of the Investigator. Disease progression must be confirmed by BICR using modified RANO 2.0.
- Adequate hematologic and organ function
- Expected survival of ≥12 months
Key Exclusion Criteria:
- Any prior anticancer therapy other than surgery (biopsy, sub-total, or gross total resection) and vorasidenib for treatment of glioma.
- Discontinued vorasidenib for toxicity or any reason other than radiographic disease progression
- Prior treatment with anti-angiogenic agents such as Avastin (bevacizumab) or investigational agents for glioma.
- Brainstem or spinal cord involvement either as primary location, site of multifocal involvement, or by significant tumor extension.
- Significant functional or neurocognitive deficits, including uncontrolled seizures
- Evidence of leptomeningeal disease.
- Use of therapeutic doses of steroids for signs/symptoms of glioma. Participants taking physiologic doses (defined as equivalent of <1.5 mg of dexamethasone equivalent) for medical conditions not related to glioma will be permitted.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Safusidenib
Safusidenib 250 mg BID |
Safusidenib administered twice daily as a single agent orally on Days 1 to 28 of a 28-day cycle. Participants may continue treatment until disease progression or another reason for discontinuation occurs. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response Rate (ORR) per modified Response Assessment in Neuro-Oncology (RANO) 2.0 assessed by Blinded Independent Central Review (BICR)
Tidsramme: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
ORR defined as the proportion of participants with the confirmed best overall response of Complete Response (CR), Partial Response (PR) or Minor Response (MR) per modified RANO 2.0, assessed by BICR |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
ORR per modified RANO 2.0 assessed by Investigator
Tidsramme: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
ORR defined as the proportion of participants with the confirmed best overall response of CR, PR or MR per modified RANO 2.0, assessed by the Investigator |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
|
Volumetric Tumor Growth Rate (TGR) by BICR
Tidsramme: From historical scans through the final scan in the study, approximately 18 months
|
TGR defined as the percentage change in tumor volume by unit of time, assessed by BICR |
From historical scans through the final scan in the study, approximately 18 months
|
|
Duration of Response (DOR) per modified RANO 2.0 assessed by BICR and by Investigator
Tidsramme: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
DOR, time from the first documentation of objective response (CR, PR, or MR) to the date of the first occurrence of radiographic disease progression per modified RANO 2.0 assessed by BICR and by the Investigator or death from any cause, whichever occurs earlier. |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
|
Time to Next Intervention (TTNI)
Tidsramme: From the date of first dose of study drug until the date of the start of another anticancer treatment or date of death, approximately 18 months
|
TTNI, defined as the time from the first dose of study drug to the initiation of first subsequent anticancer therapy or death from any cause, whichever occurs earlier |
From the date of first dose of study drug until the date of the start of another anticancer treatment or date of death, approximately 18 months
|
|
Progression Free Survival (PFS) per modified RANO 2.0 assessed by BICR and by Investigator
Tidsramme: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
PFS, defined as the time from the first dose of study drug to the date of the first occurrence of radiographic disease progression per modified RANO 2.0 assessed by BICR and by the Investigator or death from any cause, whichever occurs earlier. |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
|
Time to Response (TTR) per modified RANO 2.0 assessed by BICR and by Investigator
Tidsramme: From the date of first dose of study drug to the first documentation of objective response (CR, PR, or MR), approximately 18 months
|
TTR, defined as the time from the first dose of study drug to the first documentation of objective response (CR, PR, or MR) per modified RANO 2.0, assessed by BICR and by the Investigator |
From the date of first dose of study drug to the first documentation of objective response (CR, PR, or MR), approximately 18 months
|
|
Overall Survival (OS)
Tidsramme: From the date of first dose of study drug until the date of death, approximately 18 months
|
OS, defined as the time from the first dose of study drug to death from any cause. |
From the date of first dose of study drug until the date of death, approximately 18 months
|
|
Safety and tolerability
Tidsramme: From the date of first dose of study drug until 30 days after the date of the last dose of study drug, approximately 18 months
|
The safety and tolerability of safusidenib evaluated based on AEs graded by NCI-CTCAE version 5.0, laboratory abnormalities as graded by NCI-CTCAE version 5.0, vital signs, physical examinations, and ECGs |
From the date of first dose of study drug until 30 days after the date of the last dose of study drug, approximately 18 months
|
|
Seizure Activity
Tidsramme: From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
Evaluate seizure frequencies and severity including type of seizure, seizure-related AEs, and changes in anti-epileptic medications in participants receiving safusidenib |
From the date of first dose of study drug until the date of first documented disease progression, approximately 18 months
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- NUV-218-G209
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .